Blog Financial Times: Get vaccine new variant ready January 13, 2021 GreenLight Biosciences explain to the Financial Times how messenger RNA can help get the Covid-19 vaccine new variant ready. GreenLight Biosciences spoke to the Financial Times about making sure that any vaccine is new variant ready for Covid-19. An extract from the article is below: Andrey Zarur, chief executive of Greenlight Biosciences, a biotech company that is making a messenger RNA vaccine, said it made sense to design new vaccines to “prepare for further drift”.“Then you have a better chance of your new vaccine continuing to protect against new variants,” Mr Zarur said. Read the full article here. Find out more about how GreenLight manufactures RNA here. More of Greenlight Bioscience in the news: Bloomberg: GreenLight Is Mass-Producing RNA to Fight Crop Pests News10NBC: GreenLight Biosciences opens new RNA facility in Rochester The New York Times: Vaccines for Africa GreenLight Biosciences opens RNA production facility for the next generation of agricultural products Jennifer Raymond welcomed as SVP, CMC and Manufacturing STAT: RNA firm GreenLight Biosciences to go public in $1.2 billion deal